Rosa Announces Six Poster Presentations at the American College on Pharmacometrics 2011
In collaboration with its clients, Lithera, MediciNova, Pfizer, Vitalea, Rosa & Co will present six posters at the 2011 American College on Pharmacometrics in San Diego, CA on April 4, 2011. The posters describe the use of drug-disease modeling in pharmaceutical development.
- San Francisco, CA (1888PressRelease) March 21, 2011 - Rosa & Co. LLC, a drug development advisory firm with expertise in drug-disease modeling and simulation, today announced that it has six posters scheduled during the 2011 American College on Pharmacometrics (ACoP) meeting in San Diego, CA April 3-6, 2011. The presentations describe the use of PK/PD and physiological modeling in applications from preclinical through clinical development. Five of the posters will be presented in conjunction with Lithera, MediciNova, Pfizer, and Vitalea. The sixth poster will describe advances in the methodology of physiological modeling. After each poster has been presented at the ACoP meeting, Rosa will post links to the individual presentations at its website at www.rosaandco.com/news.
"We are pleased to share our groundbreaking work and that of our collaborators, and are honored that all of our submitted poster presentations were accepted for inclusion in the ACoP meeting," said Dr. Ron Beaver, Rosa's Founder and CEO.
About Rosa
Rosa informs our customer's most critical decisions - from preclinical through clinical development - with the creation and use of mathematical models that simulate disease physiology, drug action, patient variability, and trial outcomes. To address the full spectrum of related issues, Rosa offers two customized approaches: classic pharmacokinetic/ pharmacodynamic (PK/PD) models and Rosa's innovative PhysioPD™ models. With these approaches, Rosa's clients collaborate in model creation and testing, retain the final model, and acquire the ability to use it and understand its implications for their drug development programs. Rosa's staff have close to two decades of unparalleled professional experience in using drug-disease modeling and simulation (M&S) to accelerate drug development; they have covered hundreds of applications with dozens of clients. The Rosa team is unique in their breadth and depth of disease area experience, which includes metabolic and cardiovascular diseases, oncology, gastro-intestinal disease, inflammatory diseases, immune dysfunction (including rheumatoid arthritis), pain, skin conditions, respiratory disorders, and antibacterials/antivirals. For more information, visit www.rosaandco.com.
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam